Draig Therapeutics closes an oversubscribed $65M Series B, advancing its depression drug DT-101 through Phase 2 and toward potential Phase 3.
Ivana Magovčević-Liebisch, Draig Therapeutics CEO
July 14, 2026 07:30 AM EDTUpdated July 15, 06:22 AM
Draig nets $65M to advance depression drug aimed at rebuilding synapses
Draig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Draig bags another $65M to speed testing of brain drugs
Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
Novel Alzheimer's Drug Targeting Tau Shows Promise in Mid-Stage Trial
Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report
The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major…
Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA…
HMNC Brain Health has secured $50 million in a Series B fundraise designed to support two psychiatry programs into mid-stage…
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss;…
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and…
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the…
